Welcome to HitGen

News

Get up to date with the latest HitGen articles and join us in the events

  1. News
  2. Press Release

Press Release

  • 28 September 2022
    Vernalis Research, a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S announce a strategic collaboration in the field of RNA-targeting small molecules in neurology
    Cambridge UK, and Copenhagen, Denmark, 27 September 2022 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S (“Contera”) are pleased to announce a strategic drug discovery collaboration on an undisclosed target.
  • 05 September 2022
    Vernalis Research, a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. announce a research collaboration in the field of anti-infectives
    Cambridge UK, and Boston, US, 5 September 2022 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Unison Medicines Inc. (“Unison”) are pleased to announce a research collaboration on an undisclosed bacterial target.
  • 27 July 2022
    LoQus23 and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
    CHENGDU, China, July 27, 2022 – Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) today announced that it has entered into a research collaboration agreement with LoQus23 Therapeutics Ltd. (“LoQus23”), a private biotechnology company discovering small molecule therapies that target aberrant DNA damage repair to treat Huntington's disease and other triplet repeat diseases (TRDs). HitGen will apply its DNA-encoded library (DEL) technology platform to discover compounds that bind to certain targets that are of interest to LoQus23.
  • 20 May 2022
    Almac Discovery and HitGen Announce Strategic Research Collaboration
    Almac Discovery, the research driven drug discovery company and a member of the Almac Group, today announced a new research collaboration with HitGen Inc. (SSE: 688222.SH), a world leader in the development and application of DNA-encoded library (DEL) technology for novel chemical equity (NCE) generation. The collaboration is focused on the identification of novel compounds against selected Deubiquitinating enzymes (DUB) targets of strategic interest to Almac.
  • 13 May 2022
    HitGen and Arclight Announce DEL and TPD Collaboration in CNS Drug Discovery
    CHENGDU, China, May 13, 2022 – HitGen Inc. (“HitGen”), a Shanghai Stock Exchange STAR-listed company, and Arclight Inc. (“Arclight”), an early stage biotech company focused on innovative approaches to solving the challenges of neurodegenerative disease drug discovery and company creation, today announced a five-year strategic collaborative research and license agreement. The strategic collaboration will focus on discovery and development of innovative drugs in the central nervous system (CNS) therapeutic area using HitGen's DNA-encoded libraries (DEL) and Targeted Protein Degradation (TPD) platforms.
  • 05 May 2022
    Infographic | HitGen FY2021 Annual Report
    Infographic | HitGen FY2021 Annual Report
  • 19 April 2022
    HitGen and the PACS1 Syndrome Research Foundation announce an agreement to discover ligands that address issues related to the mutated PACS1 gene product
    CHENGDU, China, April 19, 2022 – HitGen Pharmaceuticals Inc. and the PACS1 Syndrome Research Foundation announce an agreement focused on the application of HitGen’s DNA-encoded library (DEL) technology to identify ligands that could selectively bind to the mutated PACS1 Protein and therefore serve as a treatment or a cure for patients with PACS1 Syndrome.
  • 06 April 2022
    HitGen and UPPTHERA Extend PROTAC Research Collaboration after Hit Finding Success on Undruggable Targets
    CHENGDU, China, April 6, 2022 – HitGen Inc. (“HitGen”), a Shanghai Stock Exchange STAR-listed company, today announced that the company has successfully completed the multiple-target drug discovery research projects with UPPTHERA, a Korean pharmaceutical company aiming for new drug development employing “Protein Degradation Technology”. During the collaboration, multiple undisclosed targets were screened against HitGen’s proprietary over 1 trillion DNA-encoded libraries (DELs). The majority of the targets have resulted in confirmed hits, which have high potential for PROTAC development. Now the two parties are extending the collaboration on further development of these projects and additional challenging targets.
  • 21 March 2022
    In February 2022, HitGen Inc. signed an agreement with Eli Lilly and ConfometRx to begin work on a GPCR target.
    In February 2022, HitGen Inc. signed an agreement with Eli Lilly and ConfometRx to begin work on a GPCR target.
  • 21 March 2022
    Lipigon and HitGen announce achievement of an important milestone in dyslipidemia project
    Lipigon Pharmaceuticals AB ("Lipigon") and HitGen Inc. (“HitGen”) today announced that they have identified novel small molecules that could be starting points for developing drugs targeting dyslipidemia and cardiovascular disease.

Questions?

For more details on how we can advance your innovative drug discovery projects
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information